Merck reports positive Phase 3 trial results for KEYTRUDA in HER2-positive gastric cancer
In: M2 Pharma, 2024-05-01
Zeitungsartikel
Zugriff:
M2 PHARMA-May 1, 2024-Merck reports positive Phase 3 trial results for KEYTRUDA in HER2-positive gastric cancer (C)2024 M2 COMMUNICATIONS US pharmaceutical company Merck & Co Inc (NYSE:MRK), known as MSD [...]
Titel: |
Merck reports positive Phase 3 trial results for KEYTRUDA in HER2-positive gastric cancer
|
---|---|
Zeitschrift: | M2 Pharma, 2024-05-01 |
Veröffentlichung: | 2024 |
Medientyp: | Zeitungsartikel |
Schlagwort: |
|
Sonstiges: |
|